Skip To Main Content
Yinnan Chen on Muck Rack

Yinnan Chen

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yinnan

Contact Yinnan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EZH2 deficiency suppresses colorectal cancer progression by inhibiting the mismatch repair pathway and consequently reducing extrachromosomal circular DNA formation

|
By Quanpeng Qiu, Yi Ding, Jing Han, Xiaolong Guo, Jiaqi Zhang, Yue Chen, Xinzhu Xue, Xiake Hu, Tianyu Yu, Gaixia Liu, Haowei Zhang, Qixin Li, Xiang Li, Yinnan Chen
| Nature Verified
Abstract The malignant transition of colorectal cancer (CRC) is caused by the combined action of epigenetic dysregulation and genomic instability. It is well known that EZH2-directed H3K27me3 modification is one of the main contributors to tumorigenesis; however, how it affects the DNA mismatch repair (MMR) system and the genesis of extrachromosomal circular DNA (eccDNA) remains unknown.
Open in Who Shared Issue with article?

Methyltransferase MGMT upregulation drives metastasis by activating epithelial-mesenchymal transition in KRAS mutant colon cancer

|
By Gaixia Liu, Jiaqi Zhang, Qixin Li, Xiaolong Guo, Jing Han, Guanghui Wang, Feiyu Shi, Kexuan Wang, Yi Ding, Hong Wu, Chenhao Hu, Xinzhu Xue, Yinnan Chen
| Nature Verified
Abstract Kirsten rat sarcoma (KRAS)-mutant colorectal cancer (CRC) is characterized by aggressive metastatic progression and profound therapeutic resistance. While direct inhibitors have emerged recently, their clinical application is often limited by rapid adaptive resistance, highlighting the urgent need to explore new therapeutic targets.
Open in Who Shared Issue with article?
See all 2 articles